Zoetis Inc (ZTS) Expected to Post Quarterly Sales of $1.41 Billion

Equities research analysts expect Zoetis Inc (NYSE:ZTS) to report sales of $1.41 billion for the current quarter, Zacks reports. Five analysts have made estimates for Zoetis’ earnings. The lowest sales estimate is $1.39 billion and the highest is $1.42 billion. Zoetis reported sales of $1.28 billion in the same quarter last year, which would suggest a positive year-over-year growth rate of 10.2%. The business is expected to issue its next earnings results before the market opens on Thursday, February 15th.

According to Zacks, analysts expect that Zoetis will report full-year sales of $1.41 billion for the current year, with estimates ranging from $5.24 billion to $5.27 billion. For the next fiscal year, analysts forecast that the company will report sales of $5.63 billion per share, with estimates ranging from $5.57 billion to $5.69 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Zoetis.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $0.02. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same quarter in the previous year, the firm earned $0.52 earnings per share. Zoetis’s revenue was up 8.5% on a year-over-year basis.

ZTS has been the subject of several recent analyst reports. BidaskClub lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 20th. Cantor Fitzgerald reissued a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Tuesday, September 26th. Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Thursday, October 12th. Stifel Nicolaus reissued a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Tuesday, October 24th. Finally, BMO Capital Markets set a $65.00 price objective on Zoetis and gave the stock a “hold” rating in a report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $73.00.

A number of institutional investors and hedge funds have recently modified their holdings of ZTS. Dynamic Technology Lab Private Ltd lifted its position in Zoetis by 7.3% in the second quarter. Dynamic Technology Lab Private Ltd now owns 5,901 shares of the company’s stock valued at $368,000 after purchasing an additional 401 shares during the last quarter. Balyasny Asset Management LLC lifted its position in Zoetis by 55.5% in the second quarter. Balyasny Asset Management LLC now owns 44,330 shares of the company’s stock valued at $2,765,000 after purchasing an additional 15,830 shares during the last quarter. Quantbot Technologies LP bought a new stake in Zoetis in the third quarter valued at approximately $3,972,000. Prudential PLC lifted its position in Zoetis by 4.8% in the second quarter. Prudential PLC now owns 149,389 shares of the company’s stock valued at $9,319,000 after purchasing an additional 6,811 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. lifted its position in Zoetis by 51.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,041 shares of the company’s stock valued at $1,936,000 after purchasing an additional 10,539 shares during the last quarter. 93.14% of the stock is owned by institutional investors and hedge funds.

Zoetis (NYSE ZTS) opened at $75.54 on Wednesday. Zoetis has a twelve month low of $52.00 and a twelve month high of $76.40. The company has a current ratio of 2.80, a quick ratio of 1.95 and a debt-to-equity ratio of 2.45. The company has a market capitalization of $36,810.00, a PE ratio of 39.76, a PEG ratio of 1.90 and a beta of 1.06.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, January 19th will be paid a $0.126 dividend. The ex-dividend date of this dividend is Thursday, January 18th. This represents a $0.50 annualized dividend and a yield of 0.67%. This is a positive change from Zoetis’s previous quarterly dividend of $0.11. Zoetis’s dividend payout ratio is currently 22.11%.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/17/zoetis-inc-zts-expected-to-post-quarterly-sales-of-1-41-billion-2.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Get a free copy of the Zacks research report on Zoetis (ZTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply